Biotech Co.* (Symbol) |
Pharma Co. (Symbol/Country) | Type/Product Area | Amount | Terms/Details (Date)** |
I. MODIFIED AGREEMENTS | ||||
Adolor Corp.* |
Roberts Pharmaceutical Corp. (AMEX:RPC) | Adolor exercised its option, acquired 6/98, for an exclusive worldwide license to the compound ADL 8-2698 |
ND |
Adolor will expand the clinical testing program of ADL 8-2698; Adolor made an undisclosed milestone payment to Roberts in connection with the exercise of the options further details ND (10/99) |
AlphaGene Inc.* |
NEN Life Science Products Inc.* | The companies expanded their 3/99 collaboration related to the development, manufacturing and marketing of cDNA microarrays | ND | NEN will fund the development of multiple products over the next several years, enabling AlphaGene to further advance its research on the creation of array-based products; NEN acquires the rights to manufacture any and all products resulting from the collaboration; NEN will make cash and equity investments in AlphaGene based on defined financial criteria; the agreement covers only the production of microarrays derived from known human genes primarily produced from AlphaGene's total gene inventory (9/99) |
AltaRex Corp. (Canada; TSE:AXO) | Purdue Pharma LP* |
Purdue will not exercise its option, acquired 5/99, to license AltaRex's OvaRex MAb and BrevaRex MAb, both of which are anticancer immunotherapeutic monoclonal antibody products | ND |
ND (10/14) |
Antex Biologics Inc. (OTC BB:ANTX) |
SmithKline Beecham (NYSE: SBH) |
The companies agreed to a restructuring of their four-year alliance in the field of antigen discovery | ND | SB will receive a 12% equity position in Antex through the exercise of an existing option and warrants to purchase an additional 10% of Antex common stock; Antex will continue its antigen discovery research with SB, as well as develop its own human vaccines; SB will have exclusive worldwide rights to certain Antex human vaccines in exchange for milestone payments, royalties on product sales and payment of certain other agreed upon expenses (9/99) |
Aurora Biosciences Corp. (ABSC) |
Bristol-Myers Squibb Co. (NYSE:BMY) | The companies amended their 12/96 agreement under which Aurora provides Bristol with its UHTSS drug discovery platform, screening services, and licenses to Aurora's fluorescent assay technologies |
ND | The amendment extends the screen development portion of the collaboration for an additional two years and provides a team of Aurora scientists to develop assays for use by Bristol in its screen development operations; the amendment also supports technology transfer as Bristol brings its UHTSS platform into operation; Aurora will receive contracted payments over two years, and may also receive milestone payments and royalties related to the development or commercialization of compounds identified through the use of the assays it develops (8/99) |
Avant Immunotherapeutics Inc. (AVAN) |
Novartis Pharma AG (Switzerland) |
Novartis exercised its option, acquired 10/97, to license TP10 for use in transplantation |
$6 |
A milestone payment of $6M will be paid upon the fulfillment of certain ND conditions (7/99) |
Corvas International |
Schering-Plough Corp. (NYSE:SGP) | Extension of 5/98 alliance to develop orally available inhibitors of a key protease, thought to be involved in hepatitis C virus replication | $1 |
Under the terms of the extension, Schering-Plough will continue to support preclinical development of the inhibitors under investigation through 12/99; Corvas receives $1M in additional funding (9/99) |
Cubist Pharmaceuticals Inc. (CBST) |
Merck & Co. (NYSE:MRK) |
The companies amended their 6/96 research and license agreement for the development of novel anti-infective drugs; the amendment allowed for the incorporation of two chemical classes of novel compounds, which Cubist licensed exclusively to Merck |
ND |
The original agreement provided Cubist with research support, technical license fees and milestone payments; Cubist received an undisclosed milestone payment under the amendment (8/99) |
CuraGen Corp. (CRGN) |
Glaxo Wellcome plc (NYSE:GLX) | The companies announced the completion of a collaborative research program investigating biological pathways that may be associated with Alzheimer's disease |
ND |
Completion of the program triggered an undisclosed milestone payment to CuraGen (10/99) |
Emisphere Technologies Inc. (EMIS) | Elan Corp. plc (NYSE:ELN) | The companies came to a general agreement to restructure their joint research and development venture for oral heparin |
$6 | Emisphere will fully own the technology and marketing and product rights to the venture's entire family of oral heparin products, and will assume complete responsibility for Phase III development and funding; as consideration for Elan's previous investment in the form of loan stock and equity and certain intangible assets, Emisphere will issue Elan a $20M, zero-coupon note that will accrue interest at 15% per year for a term of seven years; Elan will subscribe for Emisphere's common stock upon repayment of the note; Elan will provide Emisphere with up to $15M for Phase III trials; upon completion of the joint venture, Emisphere will receive cash payments of approximately $6M owed for past services (7/99) |
Genetronics Biomedical Ltd. (Canada; AMEX: GEB) | Ethicon Endosurgery Inc. (a subsidiary of Johnson & Johnson; NYSE: JNJ) | Responsibilities for a previous license and supply agreement between Genetronics and Ethicon Inc. will be transferred to Ethicon Endosurgery; the agreement covers electroporation therapy treatment of cancer |
ND |
Ethicon Endosurgery will help develop and clinically test Genetronics' drug delivery system and will conduct regulatory activities throughout the world, excluding Canada; upon regulatory approval, Ethicon will distribute and market products resulting from the collaboration; Genetronics will receive milestone payments and a percentage of net sales as license and manufacturing fees (8/99) |
ICAgen Inc.* | Bristol-Myers Squibb Co. (NYSE:BMY) | Bristol-Myers exercised its option to extend the companies' 10/97 collaborative agreement for the discovery and development of small-molecule, ion channel drugs to treat atrial fibrillation |
ND | Extension of the collaboration provides for continued research and development funding by Bristol-Myers; milestone and royalty payment terms of the original agreement remain the same (8/99) |
Igen International Inc. (IGEN) |
Bristol-Myers Squibb Co. (NYSE:BMY) |
The companies expanded their relationship through Bristol's acquisition of Igen's M-Series system for clinical trial applications | ND |
The expansion continues the validation of the M-Series for drug discovery research and screening, as well as drug development and preclinical/clinical trial analysis; further details ND (8/99) |
Incyte Pharmaceuticals Inc. (INCY) |
AstraZeneca (NYSE:AZN) |
AstraZeneca expanded its access to Incyte's databases, and will become the first subscriber to Incyte's LifeExpress expression database program |
ND | The expanded agreement calls for AstraZeneca to have access to Incyte's LifeSeq Gold assembled database, ZooSeq animal model database and broad access to bioinformatics tools and software; financial details ND (10/99) |
Rhone-Poulenc Rorer (NYSE:RP) |
The companies agreed to expand their 12/97 agreement to include access to Incyte's LifeSeq Gold assembled database, LifeArray expression analysis software, and a bioinformatics collaboration | ND |
Incyte could receive future milestone payments and royalties on sales of products resulting from the collaboration; further details ND (8/99) | |
Schering AG (Germany) |
The companies agreed to expand their relationship to provide Schering access to Incyte's LifeSeq Gold assembled database | ND | Incyte could receive future milestone payments and royalties on sales of products resulting from the collaboration; further details ND (9/99) | |
Isis Pharmaceuticals (ISIP) |
Boehringer Ingelheim International GmbH (Germany) |
Restructuring of 1994 collaboration for the clinical development of Isis 2302 in a number of different diseases, and the discovery of small-molecule and antisense inhibitors to various novel cell adhesion targets | ND | Isis will be solely responsible for the development and commercialization of Isis 2302 and other antisense inhibitors of cell adhesion molecules discovered during the collaboration; Boehringer will receive royalties on the sale of products resulting from the collaboration, and will become solely responsible for the development and commercialization of any small-molecule inhibitors discovered during the collaboration; Isis will receive royalties on the sale of these products; financial details ND (9/99) |
Millennium Pharmaceuticals Inc. (MLNM) |
Wyeth-Ayerst Research (the pharmaceutical division of American Home Products Corp.; NYSE:AHP) |
The companies announced an extension of their 1996 collaboration for at least an additional two years, for continued research in the area of central nervous sytem disorders; Millennium also provided Wyeth-Ayerst with a third novel candidate gene |
ND |
The original agreement provides for Millennium to receive up to $90M in licensing fees and payments to access genomic technologies and fund research; details of the extended agreement ND; an undisclosed milestone payment to Millennium was triggered by delivery of the third candidate gene (8/99) |
Myriad Genetics Inc. (MYGN) |
Bayer Corp. | Under the terms of their 1997 collaboration agreement, Bayer exercised its option to implicated in dementia pathways; financial details ND (10/99) | ND |
The proteins transferred to Bayer are based on Myriad's identification of two new genes not previously license two additional proteins for development of therapeutic products to treat dementia |
Myriad Genetics Inc. (MYGN) |
Schering AG (Germany) | The companies expanded their 1998 ProNet drug target identification collaboration to include heart disease | $10 |
Myriad will continue its drug development process, during which time it can review all data on possible drug candidates including marketing potential; Myriad will have 120 days following submission of an IND to exercise its option for 50/50 profit sharing or a fixed royalty rate; Myriad received $10M through the sale of 0.6M shares of common stock to Schering Berlin Venture Corp. and funds managed by Friedli Corporate Finance, of Zurich; Schering Berlin Venture Corp. is a wholly owned subsidiary of Schering AG's U.S. management holding company (10/99) |
Nanogen Inc. (NGEN) |
Aventis Research & Technologies GmbH Co. KG (an affiliate of Hoechst AG; NYSE:HOE) | The companies expanded their 1998 drug discovery collaboration to include the addition of two new technology development platforms |
ND |
Nanogen will retain full commercialization rights for the new programs' jointly developed drug discovery technologies, which will be licensed to Aventis R&T and its affiliates on a non-exclusive basis for internal use; financial details ND (9/99) |
Neurocrine Biosciences Inc. (NBIX) |
Janssen (a subsidiary of Johnson & Johnson; NYSE:JNJ) | The companies expanded their 2/95 research & development collaboration (R&D) to further develop corticotropin-releasing factor (CRF) receptor antagonists |
ND |
The new phase of collaboration expands the research and development efforts to identify additional CRF antagonists for the treatment of psychiatric disorders; the collaboration will continue an additional two years and will provide additional funding for a team of Neurocrine scientists to develop new compounds; Neurocrine will receive an initial payment, milestone payments and royalties on worldwide product sales (9/99) |
Nexell Therapeutics Inc. (NEXL) |
Baxter Healthcare Corp. (NYSE:BAX) |
The companies agreed to a restructuring of their agreement whereby sales, marketing and distribution responsibilities for the Isolex 300i cell selection system and other cell therapy products will be transferred from Baxter to Nexell |
ND |
The U.S. sales and distribution transfer was effective July 1, and the European transition was expected to be finalized by 3Q99; Nexell will repurchase inventory previously sold to Baxter, and will book restructuring charges associated with the transfers in the second and third quarters; Baxter will continue to manufacture and provide equipment service support for the cell selection system, and will provide a $20M line of credit, or assistance in completing a larger private placement financing; Baxter will receive royalties on sales of Isolex and related products (7/99) |
Trega Biosciences Inc. (TRGA) |
Novartis Pharma AG (Switzerland) |
The companies announced an expansion of their 5/98 R&D collaboration to add a further, undisclosed obesity-related biological target to their joint research program |
ND |
Products resulting from the collaboration will be clinically developed and exclusively commercialized worldwide by Novartis; financial terms of the expansion are covered in the original agreement, which provided a financial package to Trega in the form of research support, pre-commercialization milestones and royalties on net sales of products (10/99) |
Sangamo BioSciences Inc.* | Pfizer Inc. (NYSE:PFE) |
The companies expanded their 9/98 collaborative research agreement in the identification and validation of novel gene targets for drug discovery using Sangamo's Universal GeneTools platform | ND | Pfizer will purchase additional Universal GeneTools from Sangamo; financial details ND (10/99) |
Vertex Pharmaceuticals Inc. (VRTX) | Hoechst AG (Germany, NYSE: HOE) | The companies announced an expansion of their R&D agreement covering HMR 3480/VX-740, an orally active inhibitor of interleukin-1 beta converting enzyme, for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases |
$82 |
Hoechst will hold an exclusive, worldwide license to develop, manufacture and market the compound, as well as an exclusive option for all other compounds discovered under a previous collaboration; Hoechst will pay Vertex $20M in license fees in connection with prior research, and up to $62M for the successful development of HMR 3480/VX-740 in RA; Hoechst will retain the rights to develop the compound for additional indications; Vertex will receive similar milestones for each additional indication (9/99) |
II. TERMINATED AGREEMENTS | ||||
Cell Genesys Inc. (CEGE) |
Hoechst Marion Roussel Inc. (a unit of Hoechst AG, Germany) | Termination of collaboration agreement covering AIDS gene therapy |
$8 |
Cell Genesys will reacquire product rights to its gene therapy program; a separate license agreement for gene activation technology will continue; Cell Genesys received $8M in connection with the termination (9/99) |
CombiChem Inc. (CCHM) |
Elan Pharmaceutcals (NYSE:ELN) | Following the acquisition of CombiChem by E.I. du Pont de Nemours, CombiChem received notification that Elan will terminate the companies' collaborative agreement, effective 12/31/99 |
ND |
ND (10/99) |
IntraBiotics Pharmaceuticals Inc.* | Pharmacia & Upjohn (NYSE:PNU) | Termination of 10/97 collaboration agreement for the development of Protegrin IB-367 as an oral therapy for the treatment and prevention of oral mucositis |
ND |
IntraBiotics reacquires global rights to Progegrin IB-367; financial details ND (8/99) |
La Jolla Pharmaceutical Co. (LJPC) | Abbott Laboratories (NYSE:ABT) | Termination of license and development agreement for the experimental lupus drug LJP 394 |
ND |
La Jolla will receive all rights to LJP 394, based on the results of analyses conducted by Abbott and an independent third party of a Phase II/III trial in which the compound failed to achieve clinical endpoints; financial details ND (9/99) |
North American Vaccine Inc. (AMEX:NVX) | Abbott Laboratories (NYSE:ABT) | Abbott elected to terminate its agreement with North American Vaccine to market Certiva, the company's combination diphtheria, tetanus and acellular pertussis vaccine | ND | The termination will be effective following a nine-month transition period; there will be no refunds of past payments, payment to reacquire marketing rights, or any other type of termination penalty (10/99) |
Targeted Genetics Corp. (TGEN) |
Laboratoires Fournier SA (France) |
Termination of marketing agreement for the cancer gene therapy product tgDCC-E1A |
ND |
Targeted Genetics reacquired the European rights to tgDCC-E1A, citing a shift in product development priorities within Fournier; further details ND (8/99) |
NOTES: | ||||
# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 7/1/99 and 10/31/99. | ||||
ND 3D Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
** The dates listed are the dates of press releases. They are not necessarily the dates on which transactions took place. | ||||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | ||||
AMEX 3D American Stock Exchange; NYSE 3DNew York Stock Exchange; TSE 3D Toronto Stock Exchange | ||||
To read more on related topics, click on one of the words below.